Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE<sup>®</sup>) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.

Fauchier, Laurent; Lamblin, Nicolas; Tardu, Jean; Bellier, Lucile; Groyer, Harinala; Ittah, Deborah; Chollet, Julien; Linden, Stephan; Levy, Pierre

Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE^®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial.

Fauchier, Laurent; Lamblin, Nicolas; Tardu, Jean; Bellier, Lucile; Groyer, Harinala; Ittah, Deborah; Chollet, Julien; Linden, Stephan; Levy, Pierre.

Afiliación

Fauchier L; Cardiology Department, CHU de Tours, Université de Tours, Tours, France.
Lamblin N; Cardiology Department, CHU de Lille, Université de Lille, Lille, France.
Tardu J; Creativ-Ceutical, Paris, France. Jean.Tardu@creativ-ceutical.com.
Bellier L; Creativ-Ceutical, London, UK.
Groyer H; Boehringer Ingelheim France, Paris, France.
Ittah D; Boehringer Ingelheim France, Paris, France.
Chollet J; Boehringer Ingelheim France, Paris, France.
Linden S; Boehringer Ingelheim France, Paris, France.
Levy P; Université Paris Dauphine, Université PSL, LEDA [LEGOS], Paris, France.

Pharmacoecon Open ; 8(1): 19-30, 2024 Jan.

Article en En | MEDLINE | ID: mdl-37606866

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials / Health_economic_evaluation / Prognostic_studies Aspecto: Patient_preference Idioma: En Revista: Pharmacoecon Open Año: 2024 Tipo del documento: Article País de afiliación: Francia Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google